Cabotegravir

Cabotegravir
Names
	IUPAC name N-((2,4-Difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
Identifiers
CAS Number	1051375-10-0 ;
3D model (JSmol)	Interactive image;
ChemSpider	30829503;
KEGG	D10548;
PubChem CID	54713659;
UNII	HMH0132Z1Q ;
CompTox Dashboard (EPA)	DTXSID50146982 ;
	InChI InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1 Key: WCWSTNLSLKSJPK-LKFCYVNXSA-N; InChI=1/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1 Key: WCWSTNLSLKSJPK-LKFCYVNXBF;
	SMILES C[C@H]1CO[C@H]2N1C(=O)c3c(c(=O)c(cn3C2)C(=O)NCc4ccc(cc4F)F)O;
Properties
Chemical formula	C19H17F2N3O5
Molar mass	405.358 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	(what is ?)
	Infobox references

Cabotegravir (USAN[1] and INN[2]; also known as S/GSK1265744 or GSK744) is an investigational new drug under development for the treatment of HIV infection. It is an integrase inhibitor, with a carbamoyl pyridone structure similar to dolutegravir.[3] In investigational studies, the agent has been packaged into nanoparticles (GSK744LAP) conferring an exceptionally long biological half-life of 21–50 days following a single dose. In theory, this would make possible suppression of HIV with dosing as infrequently as once every three months.[4]

Cabotegravir is being examined in the clinical trials HPTN 083 and HPTN 084.[5][6]

References

"Adopted USANs" (PDF). American Medical Association. Retrieved 19 September 2014.
"WHO Drug Information, Vol. 28, No. 2, 2014" (PDF). WHO Publications. Retrieved 19 September 2014.
Borrell, Brendan (2014). "Long-acting shot prevents infection with HIV analogue". Nature. doi:10.1038/nature.2014.14819.
PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3–6, 2013.
"The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.
"The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Adopted USANs" (PDF). American Medical Association. Retrieved 19 September 2014.

[2] "WHO Drug Information, Vol. 28, No. 2, 2014" (PDF). WHO Publications. Retrieved 19 September 2014.

[3] Borrell, Brendan (2014). "Long-acting shot prevents infection with HIV analogue". Nature. doi:10.1038/nature.2014.14819.

[4] PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3–6, 2013.

[5] "The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.

[6] "The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.